Glipizide in T2DM Care - Latest Update from ADA 2024
Written By : Dr. Nandita Mohan
Published On 2024-07-09 06:38 GMT | Update On 2024-07-09 07:10 GMT
Advertisement
The 84th Scientific Sessions of the American Diabetes Association, held in Orlando, Florida, from June 21 to June 24, 2024, featured significant discussions on diabetes management.
One of the key highlights was from a session titled "Sulfonylureas in Type 2 Diabetes Management: Should They Stay or Should They Go?". Dr. Elbert S. Huang, a prominent expert in the field, emphasized the critical role of sulfonylureas in diabetes treatment. He remarked, "Considering the broader population, sulfonylureas are essential in formularies as many T2DM patients might otherwise go untreated. With the resources needed to treat one patient with GLP-1 receptor agonists, we could treat 177 patients with sulfonylureas." This comment is particularly relevant for resource-limited settings.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.